NCT04267848 2026-04-22
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
12 trialsNCT06498635 2026-04-22
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT07405476 2026-04-17
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Recruiting
NCT05640999 2026-04-14
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT06539468 2026-04-14
Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients
University of Michigan Rogel Cancer Center
Phase NA Recruiting
NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
NCT05812807 2026-04-07
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05873608 2026-04-06
Communication Issues in Patient and Provider Discussions of Immunotherapy
Emory University
Phase NA Recruiting
NCT05483374 2026-04-03
EURACAN
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
NCT05257551 2026-04-02
TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)
Tempus AI
Recruiting
NCT05601440 2026-03-27
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting